Live Breaking News & Updates on Luca Dezzani

Stay updated with breaking news from Luca dezzani. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Phase 2 data for ERLEADA® ▼(apalutamide) plus androgen

Study highlights opportunity for treatment intensification in this population since approximately 50 percent of patients with high-risk localised prostate. ....

Texas , United-states , Belgium , Beerse , Region-flamande , San-antonio , American , Henar-hevia , Luca-dezzani , Exchange-commission , Janssen-research-development , Johnson

J&J: new data in genitourinary cancers -January 25, 2024 at 09:34 am EST

Johnson & Johnson announced today that new clinical and real-world data will be presented via 18 abstracts at the ASCO GU symposium being held January 25-27 in San Francisco, underlining the company s. ....

San-francisco , California , United-states , Luca-dezzani , Johnson , Vice-president , Medical-affairs , Solid-tumors , Johnson-innovative , Markets ,

New Tablet Strength Provides Additional Dosing Option for Erleada

Erleada is available as a 240mg tablet for patients with non-metastatic castration-resistant and metastatic castration-sensitive prostate cancer. ....

Luca-dezzani , Janssen-scientific-affairs , Vice-president , Medical-affairs , Solid-tumor ,

New Tablet Strength Provides Additional Dosing Option for Erleada

Erleada is available as a 240mg tablet for patients with non-metastatic castration-resistant and metastatic castration-sensitive prostate cancer. ....

Luca-dezzani , Janssen-scientific-affairs , Vice-president , Medical-affairs , Solid-tumor ,